HER2-low Uncovered: A Phase 1 Retrospective Study on Testing & Concordant Treatment

Join us for the conclusion of our 2-part series on HER2-low breast cancer, featuring Dr. Paul Conkling and Dr. Erika Hamilton. They discuss the Phase 1 results from a HER2-low retrospective study evaluating HER2 testing patterns and concordant therapy in patients with HER2 metastatic breast cancer. Learn about the evolving role of HER2-low classification, ongoing education, and treatment strategies to enhance patient outcomes. Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.